ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

The owner of the Los Angeles Times discusses his fight to cure cancer and why he wants President Donald Trump to succeed in ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to confirm the efficacy and safety of combination ANKTIVA plus CPI therapy previously demonstrated in the trial QUILT 3.055 and provide evidence ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ...